Tags

Type your tag names separated by a space and hit enter

Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects.
Am Rev Respir Dis. 1987 Feb; 135(2):333-7.AR

Abstract

The bronchoconstrictor activity of an aerosol of leukotriene E4(LTE4) was compared with that of histamine in 5 normal and in 6 asthmatic subjects to define the relative potency of LTE4 between the groups using 3 indices of airway response. The FEV1 and the flow rate measured at 30% of vital capacity from partial and maximal expiratory maneuvers (V30-P and V30-M) were measured. The geometric mean (GSEM) concentration of LTE4 required to reduce the V30-P by 30% was 0.30 (1.46) mM in the normal subjects, and 0.058 (1.63) in the asthmatic subjects; LTE4 was 39-fold more potent than histamine in the former and 14-fold in the latter group. Further, we observed that when normal and asthmatic subjects were compared at a degree of bronchoconstriction resulting in a 30% decrement in the V30-P after inhaling LTE4, there was a greater response in the asthmatic group than in the normal group of the accompanying change in the FEV1. The decrements in the FEV1 were not significantly different between the 2 groups after inhaling histamine. This study demonstrates that LTE4 is a potent bronchoconstrictor agonist in humans and suggests that airway responsiveness to this agonist differs substantially with the index of bronchoconstriction used for assessment of airway response.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

3028218

Citation

Davidson, A B., et al. "Bronchoconstrictor Effects of Leukotriene E4 in Normal and Asthmatic Subjects." The American Review of Respiratory Disease, vol. 135, no. 2, 1987, pp. 333-7.
Davidson AB, Lee TH, Scanlon PD, et al. Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects. Am Rev Respir Dis. 1987;135(2):333-7.
Davidson, A. B., Lee, T. H., Scanlon, P. D., Solway, J., McFadden, E. R., Ingram, R. H., Corey, E. J., Austen, K. F., & Drazen, J. M. (1987). Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects. The American Review of Respiratory Disease, 135(2), 333-7.
Davidson AB, et al. Bronchoconstrictor Effects of Leukotriene E4 in Normal and Asthmatic Subjects. Am Rev Respir Dis. 1987;135(2):333-7. PubMed PMID: 3028218.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects. AU - Davidson,A B, AU - Lee,T H, AU - Scanlon,P D, AU - Solway,J, AU - McFadden,E R,Jr AU - Ingram,R H,Jr AU - Corey,E J, AU - Austen,K F, AU - Drazen,J M, PY - 1987/2/1/pubmed PY - 2001/3/28/medline PY - 1987/2/1/entrez SP - 333 EP - 7 JF - The American review of respiratory disease JO - Am Rev Respir Dis VL - 135 IS - 2 N2 - The bronchoconstrictor activity of an aerosol of leukotriene E4(LTE4) was compared with that of histamine in 5 normal and in 6 asthmatic subjects to define the relative potency of LTE4 between the groups using 3 indices of airway response. The FEV1 and the flow rate measured at 30% of vital capacity from partial and maximal expiratory maneuvers (V30-P and V30-M) were measured. The geometric mean (GSEM) concentration of LTE4 required to reduce the V30-P by 30% was 0.30 (1.46) mM in the normal subjects, and 0.058 (1.63) in the asthmatic subjects; LTE4 was 39-fold more potent than histamine in the former and 14-fold in the latter group. Further, we observed that when normal and asthmatic subjects were compared at a degree of bronchoconstriction resulting in a 30% decrement in the V30-P after inhaling LTE4, there was a greater response in the asthmatic group than in the normal group of the accompanying change in the FEV1. The decrements in the FEV1 were not significantly different between the 2 groups after inhaling histamine. This study demonstrates that LTE4 is a potent bronchoconstrictor agonist in humans and suggests that airway responsiveness to this agonist differs substantially with the index of bronchoconstriction used for assessment of airway response. SN - 0003-0805 UR - https://www.unboundmedicine.com/medline/citation/3028218/Bronchoconstrictor_effects_of_leukotriene_E4_in_normal_and_asthmatic_subjects_ L2 - https://www.atsjournals.org/doi/10.1164/arrd.1987.135.2.333?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -